I-35 Núria Buil Bruna
Population PK/PD modelling of the biomarker and progression free survival effects of Lanreotide Autogel in patients with non-functioning gastroenteropancreatic neuroendocrine tumors
Wednesday 10:45-12:15 |
I-39 Tim Cardilin
Modelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration Curves
Wednesday 10:45-12:15 |
I-40 Letizia Carrara
Modelling the effect of Sunitinib given alone and in combination with CPT-11 on the tumor growth in xenografted mice
Wednesday 10:45-12:15 |
I-45 Christophe Chassagnole
Modelling Synergistic Immunotherapy Combinations with Virtual Tumour
Wednesday 10:45-12:15 |
I-57 Laurent Claret
A comparison of two stage and joint tumor growth inhibition-progression free survival modeling approach to simulate clinical outcome in oncology
Wednesday 10:45-12:15 |
I-61 Ana Margarita Contreras Sandoval
Towards a platform PK/PD model for an anti-PD-L1 monoclonal antibody through a preclinical syngeneic melanoma mouse model
Wednesday 10:45-12:15 |
I-65 Camila De Almeida
PKPD-efficacy modelling of AZD9496, a novel oral selective estrogen receptor downregulator
Wednesday 10:45-12:15 |
II-23 Ahmed Suleiman
A Modeling and Simulation Framework Characterizing the Time Courses of Adverse Events in Non-Small Cell Lung Cancer Patients Treated with Erlotinib
Wednesday 15:15-16:40 |
II-33 Hoai-Thu Thai
Joint modeling of longitudinal tumor burden and time-to-event data to predict survival: application to aflibercept in second line metastatic colorectal cancer
Wednesday 15:15-16:40 |
II-36 Melanie Titze
PK/PD modeling of biomarker modulation and tumor growth inhibition by BI 893923, a novel IGF-1 receptor inhibitor
Wednesday 15:15-16:40 |
II-38 Mira Tout
The impact of initial metabolic tumor volume on rituximab pharmacokinetics and clinical response in patients with diffuse large B-cell lymphoma
Wednesday 15:15-16:40 |
II-51 Johan Wallin
Overall survival and change in tumor size in squamous NSCLC in relation to Necitumumab exposure
Wednesday 15:15-16:40 |
II-60 Paul Westwood
Population pharmacokinetic meta-analysis of ramucirumab in cancer patients
Wednesday 15:15-16:40 |
II-71 Chiara Zecchin
Modelling change in tumour size, survival and new lesions appearance in patients with ovarian cancer treated with carboplatin monotherapy or in combination with gemcitabine
Wednesday 15:15-16:40 |
III-01 Kristin Dickschen
PBPK modeling to guide experimental design in preclinical and clinical development
Thursday 10:20-11:45 |
III-08 Miro Eigenmann
Modeling of acquired resistance under TKI treatment
Thursday 10:20-11:45 |
III-15 Achim Fritsch
PK/PD Modeling of Sunitinib in Patients with Metastatic Colorectal and Renal Cell Cancer
Thursday 10:20-11:45 |
III-18 María García-Cremades
Modelling tumour growth and survival of patients with pancreatic cancer receiving Gemcitabine
Thursday 10:20-11:45 |
III-22 Ekaterina Gibiansky
Comparison of Population Pharmacokinetics and Exposure-Response Relationships of Intravenous Rituximab and Subcutaneous Rituxumab in Patients with Chronic Lymphocytic Leukemia
Thursday 10:20-11:45 |
III-31 Beatriz Guglieri-Lopez
A tumour growth inhibition model based on serum M-protein levels in patients with multiple myeloma treated by lenalidomide.
Thursday 10:20-11:45 |
III-35 Kelong Han
Tumor Growth Inhibition Modeling of Onartuzumab in Combination with Erlotinib Does Not Suggest Dose Intensification Would Improve Outcome in Patients with 2nd and 3rd Line Non-small Cell Lung Cancer
Thursday 10:20-11:45 |
III-38 Andrea Henrich
External evaluation of a PK/PD model describing the time course of paclitaxel and neutropenia in patients with advanced non-small cell lung cancer
Thursday 10:20-11:45 |
III-61 Matts Kågedal
Binning of exposures in survival analysis for oncology – A simulation study
Thursday 10:20-11:45 |
III-66 Lena Klopp-Schulze
In silico simulation study: A comparison of two population pharmacokinetic models of tamoxifen and its major metabolite endoxifen
Thursday 10:20-11:45 |
III-75 Olivia le Saux
Development and validation of a model of PSA kinetics predicting prostate cancer aggressiveness during screening
Thursday 10:20-11:45 |
III-76 SeungHwan Lee
A population pharmacokinetic analysis of CKD-516 in patients with advanced solid tumor
Thursday 10:20-11:45 |
IV-33 Ida Neldemo
Assessment of the Predictive Properties of C-Reactive Protein and Interleukin 6 on Febrile Neutropenia
Thursday 15:20-16:40 |
IV-43 Aziz Ouerdani
Effects of Bevacizumab and Everolimus for the treatment of Vestibular Schwannomas in patients with Neurofibromatosis Type 2
Thursday 15:20-16:40 |
IV-53 Alejandro Pérez-Pitarch
Growing evidence supporting therapeutic drug monitoring of erlotinib in non-small-cell lung cancer patients: a time-to-progression model.
Thursday 15:20-16:40 |
IV-54 Carlos Perez-Ruixo
Platelets dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin
Thursday 15:20-16:40 |
IV-55 Aurelie Petain
Inter-species comparison of semi-physiological pre-clinical PK/PD models to better predict the time course of myelosuppression in human: application to a novel vectorized epipodophyllotoxin (F14512)
Thursday 15:20-16:40 |
IV-57 Philippe Pierrillas
Improvement of parameter estimations in tumor growth inhibition models on xenografted animals: a novel method to handle the interval-censoring caused by experimental measurement on smaller tumor sizes
Thursday 15:20-16:40 |
IV-58 Maiara Pigatto
PK/PD modeling of tumor growth inhibition after etoposide administration in vitro and to tumor-bearing rats
Thursday 15:20-16:40 |
IV-59 Venkatesh Pilla Reddy
Modelling and simulation of concentration-depth-time profiles in the urinary bladder wall following intravesical delivery
Thursday 15:20-16:40 |
IV-75 Maria Luisa Sardu
Xenograft experiments: assessing consistency between a drug-driven and a biomarker-driven tumor growth inhibition model
Thursday 15:20-16:40 |
